Esperion Therapeutics | ESPR - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.58B 316M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cipla INR 13.25B 101.8M 2025-12
CSL USD 1.23B 498M 2025-12
Cytokinetics USD 104.9M 13.17M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Geron USD 35.42M 6.24M 2026-03
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 173M 135M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12